To assess the specific T cell subpopulations involved in the mechanism of HVEM-Fc treatment, we further depleted CD4+ T cells, CD8+ T cells, or CD25+ Tregs in tumor-bearing mice receiving HVEM-Fc treatment. The gene discussed is CD4; the disease is neoplasm.